Transcutaneous auricular vagus nerve stimulation therapy in patients with cognitively preserved structural focal epilepsy : a case series report

Shiraishi, Hideaki; Egawa, Kiyoshi; Murakami, Kaoru; Nakajima, Midori; Ueda, Yuki; Nakakubo, Sachiko; Narugami, Masashi; Kimura, Shuhei; Goto, Takeru; Hiramatsu, Yasuyoshi; Murakami, Masaaki

Transcutaneous auricular vagus nerve stimulation therapy in patients with cognitively preserved structural focal epilepsy : a case series report

Shiraishi, Hideaki; Egawa, Kiyoshi; Murakami, Kaoru et al.

Brain and development, 2024, 46(1), 49-56

Permalink : https://hdl.handle.net/2115/94206

このアイテムのアクセス数:266件（2026-10-15 12:25 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
Brain Dev 46(1) 49-56	pdf	4.64 MB	271

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/94206
タイトル	Transcutaneous auricular vagus nerve stimulation therapy in patients with cognitively preserved structural focal epilepsy : a case series report
著者	Shiraishi, Hideaki ; Egawa, Kiyoshi ; Murakami, Kaoru ; Nakajima, Midori ; Ueda, Yuki ; Nakakubo, Sachiko ; Narugami, Masashi ; Kimura, Shuhei ; Goto, Takeru ; Hiramatsu, Yasuyoshi ; Murakami, Masaaki
e-Rad_Researcher 80374411 著者名 Shiraishi, Hideaki
e-Rad_Researcher 40450829 著者名 Egawa, Kiyoshi
著者名 Murakami, Kaoru
著者名 Nakajima, Midori
著者名 Ueda, Yuki
著者名 Nakakubo, Sachiko
著者名 Narugami, Masashi
著者名 Kimura, Shuhei
著者名 Goto, Takeru
著者名 Hiramatsu, Yasuyoshi
e-Rad_Researcher 00250514 著者名 Murakami, Masaaki
言語	英語
キーワード	Transcutaneous auricular vagus nerve stimulation
	taVNS
	VNS
	Epilepsy
	Cognitive function
発行日	2024-01
出版者	Elsevier
収録物名	Brain and development
巻(号)	46(1)
ページ	49-56
抄録	Objective Transcutaneous auricular vagus nerve stimulation (taVNS) was performed in two patients suffering structural focal epilepsy with preserved intellectual ability to show the feasibility of taVNS for specific patient groups. Case Presentations Patient 1 was a 24-year-old woman with frontal lobe epilepsy who had weekly hyperkinetic seizures despite multiple anti-seizure medications. Patient 2 was a 27-year-old woman with parietal lobe epilepsy and focal cortical dysplasia in the vicinity of the lipoma in the corpus callosum. She experienced weekly focal-impaired awareness seizures even with anti-seizure medication. taVNS was applied to the left earlobe of both patients at 1.5 mA, 25 Hz, 250 μs pulse width, and 30 s stimulation with 30 s rest for 4 h per day. Over an 8-week baseline and 20 weeks of stimulation, the rate of reduction in seizure frequency was evaluated, along with quality-of-life using the Short-Form 36-Item Health survey. Results At baseline, we measured up to 11 and 12 focal seizures per week in Patient 1 and 2, respectively, with both patients achieving seizure freedom after 4 and 20 weeks taVNS, respectively. Patient 1 and 2 were observed for 18 and 14 months, respectively, including the clinical trial and follow-up observation period. Quality-of-life ratings increased in both patients, and no significant adverse events occurred during the study period. During the maintenance period after 20 weeks, seizures remained absent in Patient 1, and seizures remained reduced in Patient 2. Conclusion Our results demonstrate that taVNS may be a promising tool for structural focal epilepsy with preserved cognitive function. A multicenter double-blind clinical trial is needed to confirm the role of taVNS as an anti-seizure tool.
資源タイプ	学術雑誌論文
出版タイプ	Accepted Manuscript
権利情報	Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
権利情報	© 2023. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
PISSN	0387-7604
関連情報 (isVersionOf)	出版社版DOI https://doi.org/10.1016/j.braindev.2023.08.007